

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/20, A61K 35/74 // (C12N 1/20, C12R 1:25) (C12N 1/20, C12R 1:225)	A1	(11) International Publication Number: WO 99/07827 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/SE98/01423 (22) International Filing Date: 30 July 1998 (30.07.98) (30) Priority Data: 9702860-9 5 August 1997 (05.08.97) SE (71) Applicant (for all designated States except US): PROBI AB [SE/SE]; Forskningsbyn Idéon, S-223 70 Lund (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BUKOWSKA, Hanna [PL/PL]; ul.Bandurskiego 86/21, PL-71-685 Szczecin (PL). JOHANSSON, Marie-Louise [SE/SE]; Flygelvägen 14, S-224 72 Lund (SE). NARUSZEWICZ, Marek [PL/PL]; Zaczarowanej Rózy 12, PL-05-540 Zalesie Gorne (PL). (74) Agent: LARFELDT, Helene; Bergensträhle & Lindvall AB, P.O. Box 17704, S-118 93 Stockholm (SE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: USE OF <i>LACTOBACILLUS</i> FOR REDUCTION OF THE FIBRINOGEN LEVEL IN BLOOD (57) Abstract The invention refers to the use of a strain of <i>Lactobacillus</i> for the manufacture of a medicament for reduction of the fibrinogen level, and optionally cholesterol level, in blood. Said medicament can be utilized for the prophylaxis and/or treatment of circulatory diseases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BR	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KR	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF *LACTOBACILLUS* FOR REDUCTION OF THE FIBRINOGEN LEVEL IN BLOOD

The present invention refers to the use of strains of *Lactobacillus* being able to reduce the fibrinogen level, and optionally also the cholesterol level, in blood.

Background of the invention

Fibrinogen is a plasma protein, synthesized in the liver, which in the final step of the blood coagulation cascade by activated thrombin is converted into insoluble fibrin. Fibrin in turn, is in the fibrinolysis reaction decomposed by plasmin, also referred to as fibrinolysin, the normal mechanism for the removal of small fibrin clots from the circulation.

The plasma fibrinogen concentration increases gradually during normal aging from an average of 2.3 mg/ml at 20 years to 3.5 mg/ml at 70 years of age. The increase is coupled with about a 20 % decrease in endogenous fibrinolytic activity over the same period. Under conditions of stress or trauma the blood fibrinogen level may double or triple within 48 hours. It has been confirmed that blood fibrinogen is a major determinant of blood and plasma viscosity in the microcirculation, of red cell and platelet aggregation and in the growth of atheromatous lesions. Blood fibrinogen levels are increased and the endogenous fibrinolytic activity decreased by conditions or factors which raise plasma free fatty acid, FFA, levels, see Pickart, L., in *Pharmacology* 23: 271-280, 1981.

An increased level of fibrinogen is associated with an increased erythrocyte sedimentation rate, which in turn since long has been correlated to a risk for ischemic heart diseases. In acute myocardial infarction the level of plasma fibrinogen as well as the level of free fatty acids are increased.

Fibrinogen as a cardiovascular risk factor is described by Ernst, E., et al., *Annals of Internal Medicine* 118: 956-963, 1993. In six prospective epidemiologic studies the correlation of fibrinogen levels on the subsequent incidence of myocardial infarction, stroke and peripheral arterial occlusive disease was assessed and the causality of the association was analysed. All prospective studies showed that fibrinogen was associated with subsequent myocardial

infarction or stroke. It was concluded that fibrinogen is pathophysiologically related to cardiovascular events and can be considered a major cardiovascular risk factor.

There are several determinants of the fibrinogen level in health and disease, some of which can not be affected such as age, sex and heritage. Others which are amenable to change are lifestyle determinants such as smoking, sedentary life, diet and stress.

An increased cholesterol level, as well as an increased blood pressure are other important risk factors for heart diseases. Serum cholesterol levels generally refer to a combination of HDL, high density lipoproteins, and LDL, low density lipoproteins. Increased levels of LDL cholesterol may be associated with the pathogenesis of atherosclerosis while higher levels of HDL cholesterol appear to lower the risk of heart disease.

Prior art

There are a wide variety of antilipidemic agents which in addition to a prolonged reduction in plasma FFA levels also reduce blood fibrinogen concentrations while enhancing fibrinolytic activity apparently by decreasing hepatic synthesis of fibrinogen and antifibrinolysins, see Pickart, L., Pharmacology 23(5), 271-80, 1981. As examples of these agents, which are biochemically and structurally diverse, can be mentioned allylpropyl disulfide, the active principle from garlic and onion, acetylsalicylic acid and clofibrate, a fatty acid analogue. Most of these agents have annoying or serious side effects and more efficacious agents should be aimed at.

There are conflicting data regarding the potential hypo-cholesterolemic effect of fermented dairy products in man, and whether intake of these products has any significance in the prevention of coronary heart disease. Gilliland, S.E., et al., Applied and Environmental Microbiology, 49(2): 377-381, 1985, have found that some strains of Lactobacillus acidophilus, but not other, act directly on cholesterol in the gastrointestinal tract and may thus be beneficial in reducing serum cholesterol levels, and by this to lower the incidence of coronary heart disease. It is also reported that certain of

said strains have the ability to deconjugate bile salts. In this study pigs were used as an animal model.

There is today no substance known that lowers the fibrinogen levels in patients at risk, safely and selectively.

5

Description of the invention

It has now surprisingly been found that orally administered live Lactobacillus bacteria bring about a decrease in the serum fibrinogen level. The invention consequently refers to the use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level in blood in mammals including man.

Optionally the administered strain of Lactobacillus also brings about a decrease in the serum cholesterol level. The invention therefore also refers to the use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level as well as the cholesterol level in blood.

The invention also refers to the use of a strain of Lactobacillus in combination with an antihyperlipoprotein-emically active substance for the manufacture of a medicament for reduction of the fibrinogen level, as well as the cholesterol level, in blood. By this it will be possible to use a lower dose of the lipoprotein reducing drug, the administration of which is often associated with severe side effects.

In another aspect the invention refers to the use of a strain of Lactobacillus for the manufacture of a medicament for the prophylaxis and/or treatment of circulatory diseases, such as atherosclerosis, cardiovascular diseases, coronary heart disease, myocardial infarction, ischemic heart disease, stroke.

A preferred strain of Lactobacillus should be able to survive the passage through the stomach to the gastrointestinal tract and be able to colonize in the intestines. Two factors seem to be crucial for the exertion of ecological effects of Lactobacilli. The first is the capacity to colonize the intestine, that is to survive in high numbers for a period of time after the last administration of live bacteria. The second is the capacity to bind directly to intestinal

epithelial cells. This may be one of the factors that promotes colonization, but is not a prerequisite for colonization. The ability to adhere to the epithelium does not guarantee that the strain is able to colonize.

5 Examples of useful species of *Lactobacillus* are *L. plantarum* and *L. rhamnosus*. Different strains of of said lactobacilli are described in the International patent application WO 93/01823 referring to a process for isolation of strains of *Lactobacillus* having the ability to become
10 established on the human intestinal mucosa in vivo and also to remain thereon after oral administration for at least 10 days. Said application especially refers to two new *Lactobacillus* strains, which have been deposited according to the Budapest Agreement at the DSM - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH -, Braunschweig, Germany on July 2, 1991,
15 that is *L. plantarum* 299, number DSM 6595, and *L. casei* ssp. *rhamnosus* 271, number DSM 6594, as well as variants thereof. A preferred strain is *Lactobacillus plantarum* 299v, which has been deposited at the DSM on March 16, 1995 under number DSM
20 9843. This strain as well as other strains of *L. plantarum* are described in the International patent applica-tion WO 96/29083.

 The *Lactobacillus* strain can be administered in any food or pharmaceutical composition which can preserve the viability of the strain in the large intestine. The composi-
25 tion according to the invention can be administered in any suitable way, preferably orally or rectally, for example in the form of enema. It can also be administered enterally through a catheter inserted in the intestines via the stomach or directly in the intestines.

30 A carrier for the strain of *Lactobacillus* in the pharmaceutical composition is for example a physiologically acceptable substrate fermented by the bacterium in question, especially based on starch or milk. A suitable substrate could contain liquid or solid fibres which are not resorbed in the
35 gastro-intestinal tract. As an example of suitable, starch-containing substrates can be mentioned cereals, such as oats and wheat, corn, root vegetables such as potatoes and certain fruits such as green bananas. A preferred substrate for the pharmaceutical composition according to the invention, which

also gives the composition an excellent nutritional value, is a nutrient solution based on oatmeal, for instance as described in WO 89/08405. The fermented product can also be mixed with a foodstuff, preferably based on fruit or berries, such as rose-hip, blueberries, strawberries, but also with inert solid or liquid substances, such as saline or water.

The treatment should take place once or several times daily for a continuous period. In order to give a detectable result the strain of *Lactobacillus* should be administered in a daily dose of not less than about 10^{10} bacteria.

Biological test

The purpose of this study was to investigate the effect of a food product (ProViva®) containing *Lactobacillus plantarum* 299 v on serum lipid, especially LDL cholesterol, and fibrinogen levels in subjects with moderately elevated cholesterol concentrations.

Material and methods

The ProViva® food product was a rose-hip drink containing oats (0.75 g of oat flour, that is 0.07 g of oat fibre/100 ml). The product contains approximately 5×10^7 cfu/ml of *Lactobacillus plantarum* 299 v and about 0.035 g of DL-lactic acid/100 ml. In the manufacturing of this product the fermented oats and the rose-hip drink were made separately and then mixed together in the ratio 5 % (vol/vol) of fermented oats (containing 18.5 % (vol/vol) of oat flour) and 95 % (vol/vol) of rose-hip drink. Plain rose-hip drink, consisting of rose-hip powder, sucrose, thickening agent, citric acid, ascorbic acid and water, was used as placebo. The two products were both manufactured by Skånemejerier (Lunnarp, Sweden).

The study was performed in 30 males aged 42.6 ± 2.8 years, previously screened for gastrointestinal symptoms, medication, tobacco smoking, dietary habits and alcohol consumption. Individuals with cardiovascular disease, diabetes mellitus and arterial hypertension were excluded from the study. Body mass, height, arterial blood pressure and pulse rate were recorded and blood was collected for biochemical tests. A double-blind study with placebo was designed and the participants were randomly divided into two equal groups, to be

given ProViva® or placebo, respectively. Characteristics of the subjects of the study are given in Table 1 below.

Each subject consumed 200 ml ProViva® or placebo on each morning for six weeks and maintained the same lifestyle as before. At the end of said period the participants were examined and blood was again collected.

Cholesterol and triglyceride levels in serum were determined using enzyme kits (CHOD-PAP, GPO-PAP). HDL-cholesterol was measured after precipitation of lipoproteins containing apoB with phosphotungstic acid in the presence of Mg^{2+} . LDL-cholesterol was determined after precipitation of LDL with polyvinyl sulfate. Laboratory procedures were based on test kits from Boehringer-Mannheim. Glucose was measured using glucose oxidase and test kits from Analco (PAP) and plasma fibrinogen determinations followed the method of Clauss based on thrombin time (test kits from bioMérieux).

Table 1. Characteristics of the subjects in the two groups

Parameter	ProViva®	Placebo
Number	15	15
Age (years)	43.0 ± 2.0	42.3 ± 3.0
BMI (kg/m ²)	26.6 ± 3.7	25.9 ± 2.6
Systolic pressure (mm Hg)	133 ± 12	125 ± 15
Diastolic pressure (mm Hg)	88 ± 7	83 ± 9

Table 2. Biochemical parameters in the subjects after consumption of ProViva® or placebo

Parameter	ProViva®		Placebo	
	Before	After 6 weeks	Before	After 6 weeks
5 mg/dl				
Triglycerides	122 ± 61	121 ± 52	127 ± 42	112 ± 32
Cholesterol	233 ± 36	216 ± 33*	216 ± 31	208 ± 40
LDL-cholesterol	156 ± 36	141 ± 34*	140 ± 32	134 ± 41
HDL-cholesterol	47 ± 10	46 ± 10	48 ± 10	46 ± 8
10 Glucose	110 ± 11	112 ± 11	104 ± 10	109 ± 16
Fibrinogen	319 ± 82	276 ± 58**	320 ± 85	307 ± 60

* $p < 0.01$

** $p < 0.001$

Results

There were no significant differences between the groups as to age, body mass index (BMI), systolic or diastolic blood pressure (Table 1). Results of the biochemical test are presented in Table 2. The initial concentrations of total cholesterol, LDL-cholesterol and fibrinogen were moderately elevated in both groups, but triglyceride and HDL-cholesterol values remained within normal limits. At this point no statistically significant differences between the groups were revealed.

The results are expressed in mg/dl. Mean values and standard deviations were calculated for the biochemical parameters and subjected to the unpaired Student's t-test between groups or the paired test within each group. The level of significance was taken as $p < 0.05$. After six weeks of the experiment the level of fibrinogen in the ProViva® group fell from 319 ± 82 to 276 ± 58 mg/dl ($p < 0.001$), representing a reduction of 13.5% vs. the initial value. Similarly, the levels of total cholesterol and LDL-cholesterol were reduced by 7.3% (233 ± 33 to 216 ± 31) and 9.6% (156 ± 36 to 141 ± 34), respectively. Triglyceride, glucose and HDL-cholesterol levels remained unchanged in this group.

In the placebo group no statistically significant differences between the initial and final values were observed.

The present study confirms earlier observations that food products containing certain strains of Lactobacillus reduce blood cholesterol levels. However, for the first time it was found that a strain of Lactobacillus is effective in
5 reducing the fibrinogen level. In conclusion, diet supplementation with Lactobacillus could be beneficial to patients with moderately elevated cholesterol concentrations, reducing the risk of cardio-vascular disease.

It has already been confirmed that fibrinogen is an
10 independent risk factor of ischemic heart disease and its level in blood is regulated by genetic and environmental factors. The finding that ProViva decreases both the level of fibrinogen and cholesterol may make it a promising food product in the early
15 prevention of ischemic heart disease.

CLAIMS

1. Use of a strain of *Lactobacillus* for the manufacture of a medicament for reduction of the fibrinogen level in blood in mammals including man.
5
2. Use of a strain of *Lactobacillus* in combination with an antihyperlipoproteinemically active substance for the manufacture of a medicament for reduction of the fibrinogen level, as well as the cholesterol level, in blood.
10
3. Use according to claim 1 or 2, wherein the strain of *Lactobacillus* also reduces the cholesterol level in blood.
- 15 4. Use according to any of claims 1-3, for the manufacture of a medicament for the prophylaxis and/or treatment of circulatory diseases, such as atherosclerosis, cardiovascular diseases, coronary heart disease, myocardial infarction, ischemic heart disease, stroke.
20
5. Use according to any of claims 1-4, wherein the strain of *Lactobacillus* belongs to the species *Lactobacillus plantarum* or *Lactobacillus rhamnosus*.
- 25 6. Use according to any of claims 1-5 of *Lactobacillus plantarum* 299v, deposition number DSM 9843.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01423

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 1/20, A61K 35/74 // (C12N 1/20, C12R 1:25) (C12N 1/20, C12R 1:225)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CA, BIOSIS, MEDLINE, FOODSCIENCE, BIOTECHNOLOGY ABSTRACTS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Dialog Information Service, File 155, Medline, Dialog accession no. 09595669, Medline accession 98283630, Bukowska H. et al: "Decrease in fibrinogen and LDL-cholesterol levels upon supplementation of diet with Lactobacillus plantarum in subjects with moderately elevated cholesterol letter", Atherosclerosis (IRELAND) Apr 1998, 137 (2) p437-8 --	1-6
A	Dialog Information Services, file 5, BIOSIS PREVIEWS, Dialog accession no. 11541251, BIOSIS accession no. 98141251, Oakey H J et al: "Enzyme production of lactobacilli and the potential link with infective endocarditis"; & Journal of Applied Bacteriology 78 (2). 1995. 142-148 --	1-6

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 November 1998

Date of mailing of the international search report

11 -11- 1998

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01423

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	File WPI, Derwent accession no. 96-421913, JAPAN CHEM RES CO LTD: "Anti-thrombotic agent, inhibiting recurrent thrombosis - contains the fibrinolytic enzyme, nattokinase produced by Bacillus natto"; JP,A,8208512, 960813 --	1-6
A	EP 0671468 A1 (THE CALPIS FOOD INDUSTRY CO., LTD.), 13 Sept 1995 (13.09.95), see claims --	1-6
A	Chemical Abstracts, Volume 125, No 15, 7 Sept 1996 (07.09.96), (Columbus, Ohio, USA), Park, So-Young et al, "Effect of various lactic acid bacteria on the serum cholesterol levels in rats and resistance to acid, bile and antibiotics", THE ABSTRACT No 194329, Sanop Misaengmul Hakhoechi 1996, 24 (3), 304-310 -- -----	1-6

Information on patent family members

05/10/98

International application No.

PCT/SE 98/01423

Form PCT/ISA/210 (patent family annex) (July 1992)